UroGen officer plans more stock sales via RBC

UroGen Pharma Ltd. (symbol URGN) received a Form 144 notice indicating that officer Mark Schoenberg plans sales of common shares under Rule 144, with RBC Capital Markets LLC as the broker.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (symbol URGN) received a Form 144 notice indicating that officer Mark Schoenberg plans sales of common shares under Rule 144, with RBC Capital Markets LLC as the broker. The common stock is listed on Nasdaq. The shares to be sold were acquired through a stock option exercise from the issuer on January 27, 2023. Over the prior three months, Schoenberg reported two Rule 144 sales of UroGen common stock totaling 20,000 shares, for gross proceeds of $400,008.00 on July 9, 2026 and $350,143.00 on June 22, 2026.

Key Figures

Shares sold June 22, 2026: 10,000 shares Proceeds June 22, 2026 sale: $350,143.00 Shares sold July 9, 2026: 10,000 shares +3 more

6 metrics

Shares sold June 22, 2026 10,000 shares UroGen Pharma common stock sold by Mark Schoenberg on June 22, 2026

Proceeds June 22, 2026 sale $350,143.00 Gross proceeds for 10,000 UroGen Pharma shares sold June 22, 2026

Shares sold July 9, 2026 10,000 shares UroGen Pharma common stock sold by Mark Schoenberg on July 9, 2026

Proceeds July 9, 2026 sale $400,008.00 Gross proceeds for 10,000 UroGen Pharma shares sold July 9, 2026

Total shares sold past 3 months 20,000 shares Cumulative UroGen Pharma shares sold by Mark Schoenberg in the past three months

Acquisition date of shares to be sold 01/27/2023 Date of stock option exercise through which the shares were acquired from the issuer

Key Terms

Form 144, Rule 144, stock option exercise, securities to be sold, +1 more

5 terms

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"01/27/2023 | STOCK OPTION EXERCISE | ISSUER"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

securities to be sold financial

"144: Securities To Be Sold"

securities sold during the past 3 months financial

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does UroGen Pharma Ltd. (URGN) disclose in this Form 144?

The filing reports that officer Mark Schoenberg intends to sell UroGen Pharma common stock under Rule 144 through RBC Capital Markets LLC, with the shares having been acquired via a stock option exercise on January 27, 2023.

How many URGN shares has Mark Schoenberg sold recently under Rule 144?

Over the past three months, Mark Schoenberg reported sales totaling 20,000 shares of UroGen Pharma common stock, consisting of 10,000 shares sold on June 22, 2026 and 10,000 shares sold on July 9, 2026.

What proceeds did Mark Schoenberg receive from recent URGN stock sales?

The reported gross proceeds from recent sales were $350,143.00 for 10,000 shares on June 22, 2026 and $400,008.00 for 10,000 shares on July 9, 2026, both involving UroGen Pharma Ltd. common stock.

How were the URGN shares to be sold originally acquired by Mark Schoenberg?

The shares covered by this notice were acquired through a stock option exercise from the issuer, UroGen Pharma Ltd., on January 27, 2023, as indicated in the securities-to-be-sold section of the filing.

Which broker is handling the planned URGN stock sales for this Form 144?

The planned sales of UroGen Pharma Ltd. common stock are associated with RBC Capital Markets LLC, based in Minneapolis, which is listed as the broker in the securities information and sales history sections.

Where is UroGen Pharma Ltd. (URGN) headquartered according to this filing?

UroGen Pharma Ltd. is based in Ra’anana, Israel, at 9 Ha'Ta'asiya Street, with a listed telephone number of +972 9 770 7601, reflecting its Israeli corporate headquarters information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 01:25 PM Accepted by SEC EDGAR 08/20/2026 - 01:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763581
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UroGen Pharma Ltd.
SEC File Number	001-38079
Address of Issuer	9 HA'TA'ASIYA ST RA'ANANA ISRAEL 4365007
Phone	972 9 770 7601
Name of Person for Whose Account the Securities are To Be Sold	Schoenberg Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	RBC CAPITAL MARKETS LLC 250 NICOLLET MALL, SUITE 1700 MINNEAPOLIS MN 55401	60677	2892242.00	48880564	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/27/2023	STOCK OPTION EXERCISE	ISSUER			60677	01/27/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK SCHOENBERG C/O RBC CAPITAL MARKETS LLC 250 NICOLLET MALL MINNEAPOLIS MN 55401	UROGEN PHARMA LTD	07/09/2026	10000	400008.00
MARK SCHOENBERG C/O RBC CAPITAL MARKETS LLC 250 NICOLLET MALL MINNEAPOLIS MN 55401	UROGEN PHARMA LTD	06/22/2026	10000	350143.00

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	POA / JEFFREY EISCHENS
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)